Chinese thoracic surgery expert consensus on rational diagnosis and treatment of pulmonary nodules with a diameter≤2 cm (2024)_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

 HU Jian ¹ ,  ZHI Xiuyi ² ,  LIU Lunxu ³ , Chinese Medical Education Association Lung Cancer Medical Education Committee , Wu Jieping Medical Foundation Lung Cancer Professional Committee , Thoracic Surgery Branch of China Association for International Exchange of Medical Care , Chinese Anti-Cancer Association Lung Cancer Integrated Rehabilitation Professional Committee , Thoracic Surgeons Branch of Zhejiang Medical Doctors Association , Zhejiang Preventive Medicine Association Lung Cancer Prevention and Control Special Committee

1. Department of Thoracic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, P. R. China;
2. Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Beijing, 100053, P. R. China;
3. Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, 610041, P. R. China;

Corresponding?author：

HU Jian, Email: dr_hujian@zju.edu.cn; ZHI Xiuyi, Email: xiuyizhi2015@163.com; LIU Lunxu, Email: lunxu_liu@aliyun.com

Keywords：

Pulmonary nodules (≤2 cm); thoracic surgery; expert consensus

DOI：

10.7507/1007-4848.202406056

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

With the increasing application of low-dose computed tomography and the rising public health awareness, the early detection of pulmonary nodules has become more prevalent. Pulmonary nodules, especially those with a diameter≤2 cm, pose a critical challenge in clinical practice due to the potential risk of progressing into malignant lung lesions. Guided by the principles of "avoiding both over-treatment and mistreatment", the goal is to standardize the clinical management of pulmonary nodules. The "Chinese thoracic surgery expert consensus on rational diagnosis and treatment of pulmonary nodules with a diameter≤2 cm (2024)" was developed after extensive consultation with nearly one hundred thoracic surgery experts in China, relying on large-scale clinical study data and referencing national and international guidelines and consensus. The consensus includes 29 recommendations, focusing on specific attributes such as the size, composition, and anatomical positioning of the nodules. It proposes targeted guidelines for screening, follow-up, diagnostic criteria, and recommendations for personalized treatment, surgical approaches, and protocols for rapid postoperative recovery.

Citation： HU Jian, ZHI Xiuyi, LIU Lunxu, Chinese Medical Education Association Lung Cancer Medical Education Committee, Wu Jieping Medical Foundation Lung Cancer Professional Committee, Thoracic Surgery Branch of China Association for International Exchange of Medical Care, Chinese Anti-Cancer Association Lung Cancer Integrated Rehabilitation Professional Committee, Thoracic Surgeons Branch of Zhejiang Medical Doctors Association, Zhejiang Preventive Medicine Association Lung Cancer Prevention and Control Special Committee. Chinese thoracic surgery expert consensus on rational diagnosis and treatment of pulmonary nodules with a diameter≤2 cm (2024). Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2024, 31(8): 1077-1089. doi: 10.7507/1007-4848.202406056 Copy

1.	Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin, 2024, 74(1): 12-49.
2.	Zheng RS, Chen R, Han BF, et al. Cancer incidence and mortality in China, 2022. Zhonghua Zhong Liu Za Zhi, 2024, 46(3): 221-231.
3.	王昭玨, 趙靜, 王孟昭. 孤立性肺結節惡性概率預測模型的研究進展及臨床應用. 中國肺癌雜志, 2021, 24(9): 660-667.Wang ZJ, Zhao J, Wang MZ. Advances and clinical application of malignant probability prediction models for solitary pulmonary nodule. Chin J Lung Cancer, 2021, 24(9): 660-667.
4.	中國中西醫結合學會腫瘤專業委員會北京中醫藥學會, 腫瘤專業委員會, 肺結節全程管理共識專家組. 肺結節中西醫結合全程管理專家共識. 中國實驗方劑學雜志, 2024, 30(1): 149-159.Expert Group on Whole-Process Management of Pulmonary Nodules of the Cancer Committee of Chinese Association of Integrative Medicine, Cancer Committee of Beijing Association of Chinese Medicine. Expert consensus on whole-process management of pulmonary nodules with integrated traditional chinese and western medicine. Chin J Exper Trad Med Form, 2024, 30(1): 149-159.
5.	McWilliams A, Tammemagi MC, Mayo JR, et al. Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med, 2013, 369(10): 910-919.
6.	Siegelman SS, Zerhouni EA, Leo FP, et al. CT of the solitary pulmonary nodule. AJR Am J Roentgenol, 1980, 135(1): 1-13.
7.	Chen H, Kim AW, Hsin M, et al. The 2023 American Association for Thoracic Surgery (AATS) expert consensus document: Management of subsolid lung nodules. J Thorac Cardiovasc Surg, 2024, S0022-5223(24): 00361-1.
8.	謝輝輝, 王霄英, 林祥濤, 等. 人工智能軟件對胸部CT肺結節檢出的輔助效果初探. 醫學影像學雜志, 2022, 32(6): 944-948.Xie HH, Wang XY, Lin XT, et al. Performance of artificial intelligence-assisteddetection of lung nodules on chest CT: A preliminary study. J Med Imaging, 2022, 32(6): 944-948.
9.	劉亞斌, 周圍, 白琛, 等. 基于人工智能技術的肺部CT掃描在肺結節篩查及良惡性鑒別診斷中的應用分析. 中國CT和MRI雜志, 2022, 20(9): 52-54.Liu YB, Zhou W, Bai C, et al. Application of lung CT scan based on artificial intelligence technology in lung nodule screening and benign and malignant differential diagnosis. Chin J CT MRI, 2022, 20(9): 52-54.
10.	Wang S, Xu J, Wang R, et al. Adjuvant chemotherapy may improve prognosis after resection of stage Ⅰ lung cancer with lymphovascular invasion. J Thorac Cardiovasc Surg, 2018, 156(5): 2006-2015.
11.	周清華, 范亞光, 王穎, 等. 中國肺部結節分類、診斷與治療指南(2016年版). 中國肺癌雜志, 2016, 19(12): 793-798.Zhou QH, Fan YG, Wang Y, et al. China national guideline of classification, diagnosis and treatment for lung nodules (2016 version). Chin J Lung Cancer, 2016, 19(12): 793-798.
12.	中華醫學會呼吸病學分會肺癌學組, 中國肺癌防治聯盟專家組. 肺結節診治中國專家共識(2018年版). 中華結核和呼吸雜志, 2018, 41(10): 763-771.Lung Cancer Group of the Respiratory Disease Branch of the Chinese Medical Association, Expert Group of the China Lung Cancer Prevention and Treatment Alliance. Chinese expert consensus on the diagnosis and treatment of pulmonary nodules (2018 edition). Chin J Tuberc Respir Dis, 2018, 41(10): 763-771.
13.	吳階平醫學基金會模擬醫學部胸外科專委會. 人工智能在肺結節診治中的應用專家共識(2022年版). 中國肺癌雜志, 2022, 25(4): 219-225.Thoracic Surgery Committee, Department of Simulated Medicine, Wu Jieping Medical Foundation. Chinese experts consensus on artificial intelligence assisted management for pulmonary nodule (2022 Version). Chin J Lung Cancer, 2022, 25(4): 219-225.
14.	中國中醫腫瘤防治聯盟. 基于肺癌高風險人群篩查的肺結節中醫診療與管理專家共識. 全科醫學臨床與教育, 2023, 21(9): 772-775.China Traditional Chinese Medicine Cancer Prevention and Treatment Alliance. Expert consensus of the TCM diagnosis and treatment of pulmonary nodules basedon screening high risk population for lung cancer. Clin Educ Gener Pract, 2023, 21(9): 772-775.
15.	National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med, 2011, 365(5): 395-409.
16.	Horeweg N, van der Aalst CM, Vliegenthart R, et al. Volumetric computed tomography screening for lung cancer: Three rounds of the NELSON trial. Eur Respir J, 2013, 42(6): 1659-1667.
17.	Li N, Tan F, Chen W, et al. One-off low-dose CT for lung cancer screening in China: A multicentre, population-based, prospective cohort study. Lancet Respir Med, 2022, 10(4): 378-391.
18.	Detterbeck FC, Mazzone PJ, Naidich DP, et al. Screening for lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 2013, 143(5 Suppl): e78S-e92S.
19.	Callister ME, Baldwin DR, Akram AR, et al. British Thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax, 2015, 70 Suppl 2: ii1-ii54.
20.	李納, 孫楠, 李小玲, 等. 健康體檢人群肺結節患病特征及其影響因素分析. 臨床肺科雜志, 2024, 29(4): 546-550.Li N, Sun N, Li XL, et al. Analysis of the characteristics and innuencing factors of pulmonary nodules in health examination population. J Clin Pulm Med, 2024, 29(4): 546-550.
21.	孟誠, 鄔芝雅, 馮繼鋒. 肺結節風險分層評估的研究進展. 中國現代醫生, 2023, 61(26): 141-144.Meng C, Wu ZY, Feng JF. Research progress on risk stratification assessment of pulmonary nodules. Chin Modern Doctor, 2023, 61(26): 141-144.
22.	Bankier AA, MacMahon H, Goo JM, et al. Recommendations for measuring pulmonary nodules at CT: A statement from the Fleischner Society. Radiology, 2017, 285(2): 584-600.
23.	Check DK, Albers KB, Uppal KM, et al. Examining the role of access to care: Racial/ethnic differences in receipt of resection for early-stage non-small cell lung cancer among integrated system members and non-members. Lung Cancer, 2018, 125: 51-56.
24.	Choi S, Yoon DW, Shin S, et al. Importance of lymph node evaluation in ≤2-cm pure-solid non-small cell lung cancer. Ann Thorac Surg, 2024, 117(3): 586-593.
25.	Horeweg N, van Rosmalen J, Heuvelmans MA, et al. Lung cancer probability in patients with CT-detected pulmonary nodules: A prespecified analysis of data from the NELSON trial of low-dose CT screening. Lancet Oncol, 2014, 15(12): 1332-1341.
26.	Herder GJ, van Tinteren H, Golding RP, et al. Clinical prediction model to characterize pulmonary nodules: Validation and added value of 18F-fluorodeoxyglucose positron emission tomography. Chest, 2005, 128(4): 2490-2496.
27.	MacMahon H, Naidich DP, Goo JM, et al. Guidelines for management of incidental pulmonary nodules detected on CT images: From the Fleischner Society 2017. Radiology, 2017, 284(1): 228-243.
28.	Fong KM, Rosenthal A, Giroux DJ, et al. The IASLC Lung Cancer Staging Project: Proposals for the revision of the M descriptors in the forthcoming 9th edition of the TNM classification of lung cancer. J Thorac Oncol, 2024, S1556-0864(24): 00060-1.1556-1864.
29.	Yang SM, Wang ML, Hung MH, et al. Tubeless uniportal thoracoscopic wedge resection for peripheral lung nodules. Ann Thorac Surg, 2017, 103(2): 462-468.
30.	Liu CY, Hsu PK, Leong KI, et al. Is tubeless uniportal video-assisted thoracic surgery for pulmonary wedge resection a safe procedure? Eur J Cardiothorac Surg, 2020, 58(Suppl_1): i70-i76.
31.	Kitami A, Sano F, Hayashi S, et al. Correlation between histological invasiveness and the computed tomography value in pure ground-glass nodules. Surg Today, 2016, 46(5): 593-598.
32.	Ichinose J, Kawaguchi Y, Nakao M, et al. Utility of maximum CT value in predicting the invasiveness of pure ground-glass nodules. Clin Lung Cancer, 2020, 21(3): 281-287.
33.	Noguchi M. Stepwise progression of pulmonary adenocarcinoma--clinical and molecular implications. Cancer Metastasis Rev, 2010, 29(1): 15-21.
34.	Xiang W, Xing Y, Jiang S, et al. Morphological factors differentiating between early lung adenocarcinomas appearing as pure ground-glass nodules measuring ≤10 mm on thin-section computed tomography. Cancer Imaging, 2014, 14(1): 33.
35.	劉寶東, 陳海泉, 劉倫旭, 等. 肺結節多學科微創診療中國專家共識. 中國胸心血管外科臨床雜志, 2023, 30(8): 1061-1074.Liu BD, Chen HQ, Liu LX, et al. Chinese expert consensus on multidisciplinary minimally invasive diagnosis andtreatment of pulmonary nodules. Chin J Clin Thorac Cardiovasc Surg, 2023, 30(8): 1061-1074.
36.	Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg, 1995, 60(3): 615-622.
37.	Muraoka M, Oka T, Akamine S, et al. Video-assisted thoracic surgery lobectomy reduces the morbidity after surgery for stage Ⅰ non-small cell lung cancer. Jpn J Thorac Cardiovasc Surg, 2006, 54(2): 49-55.
38.	Sugi K, Kaneda Y, Esato K. Video-assisted thoracoscopic lobectomy achieves a satisfactory long-term prognosis in patients with clinical stage ⅠA lung cancer. World J Surg, 2000, 24(1): 27-30.
39.	Altorki NK, Yip R, Hanaoka T, et al. Sublobar resection is equivalent to lobectomy for clinical stage 1A lung cancer in solid nodules. J Thorac Cardiovasc Surg, 2014, 147(2): 754-762.
40.	Onaitis MW, Furnary AP, Kosinski AS, et al. Equivalent survival between lobectomy and segmentectomy for clinical stage ⅠA lung cancer. Ann Thorac Surg, 2020, 110(6): 1882-1891.
41.	Saji H, Okada M, Tsuboi M, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): A multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet, 2022, 399(10335): 1607-1617.
42.	Suzuki K, Koike T, Asakawa T, et al. A prospective radiological study of thin-section computed tomography to predict pathological noninvasiveness in peripheral clinical ⅠA lung cancer (Japan Clinical Oncology Group 0201). J Thorac Oncol, 2011, 6(4): 751-756.
43.	Tsutani Y, Miyata Y, Nakayama H, et al. Appropriate sublobar resection choice for ground glass opacity-dominant clinical stage ⅠA lung adenocarcinoma: Wedge resection or segmentectomy. Chest, 2014, 145(1): 66-71.
44.	Aokage K, Suzuki K, Saji H, et al. Segmentectomy for ground-glass-dominant lung cancer with a tumour diameter of 3 cm or less including ground-glass opacity (JCOG1211): A multicentre, single-arm, confirmatory, phase 3 trial. Lancet Respir Med, 2023, 11(6): 540-549.
45.	Zhang Y, Fu F, Wen Z, et al. Segment location and ground glass opacity ratio reliably predict node-negative status in lung cancer. Ann Thorac Surg, 2020, 109(4): 1061-1068.
46.	Zhang Y, Deng C, Zheng Q, et al. Selective mediastinal lymph node dissection strategy for clinical T1N0 invasive lung cancer: A Prospective, multicenter, clinical trial. J Thorac Oncol, 2023, 18(7): 931-939.
47.	Warth A, Muley T, Meister M, et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol, 2012, 30(13): 1438-1446.
48.	Hung JJ, Jeng WJ, Chou TY, et al. Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification on death and recurrence in completely resected stageⅠ lung adenocarcinoma. Ann Surg, 2013, 258(6): 1079-1086.
49.	Zhang J, Wu J, Tan Q, et al. Why do pathological stage ⅠA lung adenocarcinomas vary from prognosis?: A clinicopathologic study of 176 patients with pathological stage ⅠA lung adenocarcinoma based on the IASLC/ATS/ERS classification. J Thorac Oncol, 2013, 8(9): 1196-1202.
50.	Yoshizawa A, Sumiyoshi S, Sonobe M, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: Analysis of 440 Japanese patients. J Thorac Oncol, 2013, 8(1): 52-61.
51.	Nitadori J, Bograd AJ, Kadota K, et al. Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2 cm or smaller. J Natl Cancer Inst, 2013, 105(16): 1212-1220.
52.	Su H, Xie H, Dai C, et al. Procedure-specific prognostic impact of micropapillary subtype may guide resection strategy in small-sized lung adenocarcinomas: A multicenter study. Ther Adv Med Oncol, 2020, 12: 1758835920937893.
53.	Zhao ZR, To KF, Mok TS, et al. Is there significance in identification of non-predominant micropapillary or solid components in early-stage lung adenocarcinoma? Interact Cardiovasc Thorac Surg, 2017, 24(1): 121-125.
54.	陳昶, 朱余明, 姜格寧, 等. 肺段切除術和肺葉切除術治療直徑≤2 cm且術中冰凍證實微乳頭和實性亞型陰性肺腺癌的多中心隨機對照研究. 中國胸心血管外科臨床雜志, 2021, 28(11): 1292-1298.Chen C, Zhu YM, Jiang GN, et al. Comparison of segmentectomy versus lobectomy for ≤2 cm lung adenocarcinoma with micropapillary and solid subtype negative by intraoperative frozen sections: A multi-center randomized controlled trial. Chin J Clin Thorac Cardiovasc Surg, 2021, 28(11): 1292-1298.
55.	Zhou D, Yao T, Huang X, et al. Real-world comprehensive diagnosis and "Surgery+X" treatment strategy of early-stage synchronous multiple primary lung cancer. Cancer Med, 2023, 12(12): 12996-13006.
56.	Gonzalez M, Zellweger M, Nardini M, et al. Precision surgery in lung metastasectomy. Future Oncol, 2020, 16(16s): 7-13.
57.	Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol, 2011, 8(6): 378-382.
58.	Samadzadeh Tabrizi N, Gallant B, Harris E, et al. Contemporary incidence of synchronous multiple primary lung cancers and survival in the era of lung cancer screening. Innovations (Phila), 2024, 19(1): 23-29.
59.	Detterbeck FC, Nicholson AG, Franklin WA, et al. The IASLC Lung Cancer Staging Project: Summary of proposals for revisions of the classification of lung cancers with multiple pulmonary sites of involvement in the forthcoming eighth edition of the TNM classification. J Thorac Oncol, 2016, 11(5): 639-650.
60.	Martini N, Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg, 1975, 70(4): 606-612.
61.	Kozower BD, Larner JM, Detterbeck FC, et al. Special treatment issues in non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 2013, 143(5 Suppl): e369S-e399S.
62.	Kang X, Zhang C, Zhou H, et al. Multiple pulmonary resections for synchronous and metachronous lung cancer at two Chinese centers. Ann Thorac Surg, 2020, 109(3): 856-863.
63.	Nie Y, Wang X, Yang F, et al. Surgical prognosis of synchronous multiple primary lung cancer: Systematic review and meta-analysis. Clin Lung Cancer, 2021, 22(4): 341-350.
64.	姜格寧, 陳昶, 朱余明, 等. 上海市肺科醫院磨玻璃結節早期肺腺癌的診療共識(第一版). 中國肺癌雜志, 2018, 21(3): 147-159.Jiang G, Chen C, Zhu Y, et al. Shanghai pulmonary hospital experts consensus on the management of ground-glass nodules suspected as lung adenocarcinoma (version 1). Chin J Lung Cancer, 2018, 21(3): 147-159.
65.	韓丁培, 嚴越, 曹羽欽, 等. 加速康復外科理念在胸外科臨床實踐指導的瑞金醫院專家共識. 山東大學學報(醫學版), 2022, 60(11): 11-16.Han DP, Yan Y, Cao YQ, et al. Expert consensus of Ruijin Hospital on the concept of enhanced recoveryafter surgery in the clinical practice of thoracic surgery. J Shandong Univ (Health Sci), 2022, 60(11): 11-16.
66.	支修益, 劉倫旭, 中國胸外科圍手術期氣道管理指南(2020版)編寫委員會. 中國胸外科圍手術期氣道管理指南(2020版). 中國胸心血管外科臨床雜志, 2021, 28(3): 251-262.Zhi XY, Liu LX, Writing Committee of Chinese Guidelines for Perioperative Airway Management in Thoracic Surgery (2020 edition). Chinese guidelines for perioperative airway management in thoracic surgery (2020 edition). Chin J Clin Thorac Cardiovasc Surg, 2021, 28(3): 251-262.
67.	高樹庚. 加速康復外科在肺癌圍術期管理中的應用. 山東大學學報(醫學版), 2022, 60(11): 1-10.Gao SG. Application of enhanced recovery after surgeryin perioperative management of lung cancer. J Shandong Univ (Health Sci), 2022, 60(11): 1-10.
68.	郭儐, 劉志承, 羅鴻萍, 等. 智慧醫療時代ERAS發展的新機遇. 嶺南現代臨床外科, 2021, 21(3): 253-256.Guo J, Liu ZC, Luo HP, et al. New opportunities for ERAS in the era of intelligent medicine. Lingnan Mod Clin Surg, 2021, 21(3): 253-256.
69.	石文惠, 劉拓, 趙玉明. 數字療法應用與發展展望. 中國醫學前沿雜志(電子版), 2023, 15(12): 8-11.Shi WH, Liu T, Zhao YM. Application and development perspectives of digital therapeutics. Chin J Front Med Sci (Electronic Version), 2023, 15(12): 8-11.
70.	徐宜蕙, 張一帆, 李楊, 等. 美國FDA批準的數字療法產品臨床試驗設計研究. 中國醫學裝備, 2022, 19(11): 1-7.Xu YH, Zhang YF, Li Y, et al. Study on the design of clinical trial of approved DTx by FDA. Chin Med Equip, 2022, 19(11): 1-7.
71.	Mogk JM, Matson TE, Caldeiro RM, et al. Implementation and workflow strategies for integrating digital therapeutics for alcohol use disorders into primary care: A qualitative study. Addict Sci Clin Pract, 2023, 18(1): 27.
72.	Kumbara AB, Iyer AK, Green CR, et al. Impact of a combined continuous glucose monitoring-digital health solution on glucose metrics and self-management behavior for adults with type 2 diabetes: Real-world, observational study. JMIR Diabetes, 2023, 8: e47638.
73.	吳一龍, 陸舜, 程穎, 等. 非小細胞肺癌分子殘留病灶專家共識. 循證醫學, 2021, 21(3): 129-135.Wu YL, Lu S, Cheng Y, et al. Practice guideline and specialists, consensus expert consensus of molecular residual disease for non-small cell lung cancer. J Evid Based Med, 2021, 21(3): 129-135.
74.	Gale D, Heider K, Ruiz-Valdepenas A, et al. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer. Ann Oncol, 2022, 33(5): 500-510.
75.	Xia S, Ye J, Chen Y, et al. Parallel serial assessment of somatic mutation and methylation profile from circulating tumor DNA predicts treatment response and impending disease progression in osimertinib-treated lung adenocarcinoma patients. Transl Lung Cancer Res, 2019, 8(6): 1016-1028.

1. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin, 2024, 74(1): 12-49.
2. Zheng RS, Chen R, Han BF, et al. Cancer incidence and mortality in China, 2022. Zhonghua Zhong Liu Za Zhi, 2024, 46(3): 221-231.
3. 王昭玨, 趙靜, 王孟昭. 孤立性肺結節惡性概率預測模型的研究進展及臨床應用. 中國肺癌雜志, 2021, 24(9): 660-667.Wang ZJ, Zhao J, Wang MZ. Advances and clinical application of malignant probability prediction models for solitary pulmonary nodule. Chin J Lung Cancer, 2021, 24(9): 660-667.
4. 中國中西醫結合學會腫瘤專業委員會北京中醫藥學會, 腫瘤專業委員會, 肺結節全程管理共識專家組. 肺結節中西醫結合全程管理專家共識. 中國實驗方劑學雜志, 2024, 30(1): 149-159.Expert Group on Whole-Process Management of Pulmonary Nodules of the Cancer Committee of Chinese Association of Integrative Medicine, Cancer Committee of Beijing Association of Chinese Medicine. Expert consensus on whole-process management of pulmonary nodules with integrated traditional chinese and western medicine. Chin J Exper Trad Med Form, 2024, 30(1): 149-159.
5. McWilliams A, Tammemagi MC, Mayo JR, et al. Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med, 2013, 369(10): 910-919.
6. Siegelman SS, Zerhouni EA, Leo FP, et al. CT of the solitary pulmonary nodule. AJR Am J Roentgenol, 1980, 135(1): 1-13.
7. Chen H, Kim AW, Hsin M, et al. The 2023 American Association for Thoracic Surgery (AATS) expert consensus document: Management of subsolid lung nodules. J Thorac Cardiovasc Surg, 2024, S0022-5223(24): 00361-1.
8. 謝輝輝, 王霄英, 林祥濤, 等. 人工智能軟件對胸部CT肺結節檢出的輔助效果初探. 醫學影像學雜志, 2022, 32(6): 944-948.Xie HH, Wang XY, Lin XT, et al. Performance of artificial intelligence-assisteddetection of lung nodules on chest CT: A preliminary study. J Med Imaging, 2022, 32(6): 944-948.
9. 劉亞斌, 周圍, 白琛, 等. 基于人工智能技術的肺部CT掃描在肺結節篩查及良惡性鑒別診斷中的應用分析. 中國CT和MRI雜志, 2022, 20(9): 52-54.Liu YB, Zhou W, Bai C, et al. Application of lung CT scan based on artificial intelligence technology in lung nodule screening and benign and malignant differential diagnosis. Chin J CT MRI, 2022, 20(9): 52-54.
10. Wang S, Xu J, Wang R, et al. Adjuvant chemotherapy may improve prognosis after resection of stage Ⅰ lung cancer with lymphovascular invasion. J Thorac Cardiovasc Surg, 2018, 156(5): 2006-2015.
11. 周清華, 范亞光, 王穎, 等. 中國肺部結節分類、診斷與治療指南(2016年版). 中國肺癌雜志, 2016, 19(12): 793-798.Zhou QH, Fan YG, Wang Y, et al. China national guideline of classification, diagnosis and treatment for lung nodules (2016 version). Chin J Lung Cancer, 2016, 19(12): 793-798.
12. 中華醫學會呼吸病學分會肺癌學組, 中國肺癌防治聯盟專家組. 肺結節診治中國專家共識(2018年版). 中華結核和呼吸雜志, 2018, 41(10): 763-771.Lung Cancer Group of the Respiratory Disease Branch of the Chinese Medical Association, Expert Group of the China Lung Cancer Prevention and Treatment Alliance. Chinese expert consensus on the diagnosis and treatment of pulmonary nodules (2018 edition). Chin J Tuberc Respir Dis, 2018, 41(10): 763-771.
13. 吳階平醫學基金會模擬醫學部胸外科專委會. 人工智能在肺結節診治中的應用專家共識(2022年版). 中國肺癌雜志, 2022, 25(4): 219-225.Thoracic Surgery Committee, Department of Simulated Medicine, Wu Jieping Medical Foundation. Chinese experts consensus on artificial intelligence assisted management for pulmonary nodule (2022 Version). Chin J Lung Cancer, 2022, 25(4): 219-225.
14. 中國中醫腫瘤防治聯盟. 基于肺癌高風險人群篩查的肺結節中醫診療與管理專家共識. 全科醫學臨床與教育, 2023, 21(9): 772-775.China Traditional Chinese Medicine Cancer Prevention and Treatment Alliance. Expert consensus of the TCM diagnosis and treatment of pulmonary nodules basedon screening high risk population for lung cancer. Clin Educ Gener Pract, 2023, 21(9): 772-775.
15. National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med, 2011, 365(5): 395-409.
16. Horeweg N, van der Aalst CM, Vliegenthart R, et al. Volumetric computed tomography screening for lung cancer: Three rounds of the NELSON trial. Eur Respir J, 2013, 42(6): 1659-1667.
17. Li N, Tan F, Chen W, et al. One-off low-dose CT for lung cancer screening in China: A multicentre, population-based, prospective cohort study. Lancet Respir Med, 2022, 10(4): 378-391.
18. Detterbeck FC, Mazzone PJ, Naidich DP, et al. Screening for lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 2013, 143(5 Suppl): e78S-e92S.
19. Callister ME, Baldwin DR, Akram AR, et al. British Thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax, 2015, 70 Suppl 2: ii1-ii54.
20. 李納, 孫楠, 李小玲, 等. 健康體檢人群肺結節患病特征及其影響因素分析. 臨床肺科雜志, 2024, 29(4): 546-550.Li N, Sun N, Li XL, et al. Analysis of the characteristics and innuencing factors of pulmonary nodules in health examination population. J Clin Pulm Med, 2024, 29(4): 546-550.
21. 孟誠, 鄔芝雅, 馮繼鋒. 肺結節風險分層評估的研究進展. 中國現代醫生, 2023, 61(26): 141-144.Meng C, Wu ZY, Feng JF. Research progress on risk stratification assessment of pulmonary nodules. Chin Modern Doctor, 2023, 61(26): 141-144.
22. Bankier AA, MacMahon H, Goo JM, et al. Recommendations for measuring pulmonary nodules at CT: A statement from the Fleischner Society. Radiology, 2017, 285(2): 584-600.
23. Check DK, Albers KB, Uppal KM, et al. Examining the role of access to care: Racial/ethnic differences in receipt of resection for early-stage non-small cell lung cancer among integrated system members and non-members. Lung Cancer, 2018, 125: 51-56.
24. Choi S, Yoon DW, Shin S, et al. Importance of lymph node evaluation in ≤2-cm pure-solid non-small cell lung cancer. Ann Thorac Surg, 2024, 117(3): 586-593.
25. Horeweg N, van Rosmalen J, Heuvelmans MA, et al. Lung cancer probability in patients with CT-detected pulmonary nodules: A prespecified analysis of data from the NELSON trial of low-dose CT screening. Lancet Oncol, 2014, 15(12): 1332-1341.
26. Herder GJ, van Tinteren H, Golding RP, et al. Clinical prediction model to characterize pulmonary nodules: Validation and added value of 18F-fluorodeoxyglucose positron emission tomography. Chest, 2005, 128(4): 2490-2496.
27. MacMahon H, Naidich DP, Goo JM, et al. Guidelines for management of incidental pulmonary nodules detected on CT images: From the Fleischner Society 2017. Radiology, 2017, 284(1): 228-243.
28. Fong KM, Rosenthal A, Giroux DJ, et al. The IASLC Lung Cancer Staging Project: Proposals for the revision of the M descriptors in the forthcoming 9th edition of the TNM classification of lung cancer. J Thorac Oncol, 2024, S1556-0864(24): 00060-1.1556-1864.
29. Yang SM, Wang ML, Hung MH, et al. Tubeless uniportal thoracoscopic wedge resection for peripheral lung nodules. Ann Thorac Surg, 2017, 103(2): 462-468.
30. Liu CY, Hsu PK, Leong KI, et al. Is tubeless uniportal video-assisted thoracic surgery for pulmonary wedge resection a safe procedure? Eur J Cardiothorac Surg, 2020, 58(Suppl_1): i70-i76.
31. Kitami A, Sano F, Hayashi S, et al. Correlation between histological invasiveness and the computed tomography value in pure ground-glass nodules. Surg Today, 2016, 46(5): 593-598.
32. Ichinose J, Kawaguchi Y, Nakao M, et al. Utility of maximum CT value in predicting the invasiveness of pure ground-glass nodules. Clin Lung Cancer, 2020, 21(3): 281-287.
33. Noguchi M. Stepwise progression of pulmonary adenocarcinoma--clinical and molecular implications. Cancer Metastasis Rev, 2010, 29(1): 15-21.
34. Xiang W, Xing Y, Jiang S, et al. Morphological factors differentiating between early lung adenocarcinomas appearing as pure ground-glass nodules measuring ≤10 mm on thin-section computed tomography. Cancer Imaging, 2014, 14(1): 33.
35. 劉寶東, 陳海泉, 劉倫旭, 等. 肺結節多學科微創診療中國專家共識. 中國胸心血管外科臨床雜志, 2023, 30(8): 1061-1074.Liu BD, Chen HQ, Liu LX, et al. Chinese expert consensus on multidisciplinary minimally invasive diagnosis andtreatment of pulmonary nodules. Chin J Clin Thorac Cardiovasc Surg, 2023, 30(8): 1061-1074.
36. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg, 1995, 60(3): 615-622.
37. Muraoka M, Oka T, Akamine S, et al. Video-assisted thoracic surgery lobectomy reduces the morbidity after surgery for stage Ⅰ non-small cell lung cancer. Jpn J Thorac Cardiovasc Surg, 2006, 54(2): 49-55.
38. Sugi K, Kaneda Y, Esato K. Video-assisted thoracoscopic lobectomy achieves a satisfactory long-term prognosis in patients with clinical stage ⅠA lung cancer. World J Surg, 2000, 24(1): 27-30.
39. Altorki NK, Yip R, Hanaoka T, et al. Sublobar resection is equivalent to lobectomy for clinical stage 1A lung cancer in solid nodules. J Thorac Cardiovasc Surg, 2014, 147(2): 754-762.
40. Onaitis MW, Furnary AP, Kosinski AS, et al. Equivalent survival between lobectomy and segmentectomy for clinical stage ⅠA lung cancer. Ann Thorac Surg, 2020, 110(6): 1882-1891.
41. Saji H, Okada M, Tsuboi M, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): A multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet, 2022, 399(10335): 1607-1617.
42. Suzuki K, Koike T, Asakawa T, et al. A prospective radiological study of thin-section computed tomography to predict pathological noninvasiveness in peripheral clinical ⅠA lung cancer (Japan Clinical Oncology Group 0201). J Thorac Oncol, 2011, 6(4): 751-756.
43. Tsutani Y, Miyata Y, Nakayama H, et al. Appropriate sublobar resection choice for ground glass opacity-dominant clinical stage ⅠA lung adenocarcinoma: Wedge resection or segmentectomy. Chest, 2014, 145(1): 66-71.
44. Aokage K, Suzuki K, Saji H, et al. Segmentectomy for ground-glass-dominant lung cancer with a tumour diameter of 3 cm or less including ground-glass opacity (JCOG1211): A multicentre, single-arm, confirmatory, phase 3 trial. Lancet Respir Med, 2023, 11(6): 540-549.
45. Zhang Y, Fu F, Wen Z, et al. Segment location and ground glass opacity ratio reliably predict node-negative status in lung cancer. Ann Thorac Surg, 2020, 109(4): 1061-1068.
46. Zhang Y, Deng C, Zheng Q, et al. Selective mediastinal lymph node dissection strategy for clinical T1N0 invasive lung cancer: A Prospective, multicenter, clinical trial. J Thorac Oncol, 2023, 18(7): 931-939.
47. Warth A, Muley T, Meister M, et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol, 2012, 30(13): 1438-1446.
48. Hung JJ, Jeng WJ, Chou TY, et al. Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification on death and recurrence in completely resected stageⅠ lung adenocarcinoma. Ann Surg, 2013, 258(6): 1079-1086.
49. Zhang J, Wu J, Tan Q, et al. Why do pathological stage ⅠA lung adenocarcinomas vary from prognosis?: A clinicopathologic study of 176 patients with pathological stage ⅠA lung adenocarcinoma based on the IASLC/ATS/ERS classification. J Thorac Oncol, 2013, 8(9): 1196-1202.
50. Yoshizawa A, Sumiyoshi S, Sonobe M, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: Analysis of 440 Japanese patients. J Thorac Oncol, 2013, 8(1): 52-61.
51. Nitadori J, Bograd AJ, Kadota K, et al. Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2 cm or smaller. J Natl Cancer Inst, 2013, 105(16): 1212-1220.
52. Su H, Xie H, Dai C, et al. Procedure-specific prognostic impact of micropapillary subtype may guide resection strategy in small-sized lung adenocarcinomas: A multicenter study. Ther Adv Med Oncol, 2020, 12: 1758835920937893.
53. Zhao ZR, To KF, Mok TS, et al. Is there significance in identification of non-predominant micropapillary or solid components in early-stage lung adenocarcinoma? Interact Cardiovasc Thorac Surg, 2017, 24(1): 121-125.
54. 陳昶, 朱余明, 姜格寧, 等. 肺段切除術和肺葉切除術治療直徑≤2 cm且術中冰凍證實微乳頭和實性亞型陰性肺腺癌的多中心隨機對照研究. 中國胸心血管外科臨床雜志, 2021, 28(11): 1292-1298.Chen C, Zhu YM, Jiang GN, et al. Comparison of segmentectomy versus lobectomy for ≤2 cm lung adenocarcinoma with micropapillary and solid subtype negative by intraoperative frozen sections: A multi-center randomized controlled trial. Chin J Clin Thorac Cardiovasc Surg, 2021, 28(11): 1292-1298.
55. Zhou D, Yao T, Huang X, et al. Real-world comprehensive diagnosis and "Surgery+X" treatment strategy of early-stage synchronous multiple primary lung cancer. Cancer Med, 2023, 12(12): 12996-13006.
56. Gonzalez M, Zellweger M, Nardini M, et al. Precision surgery in lung metastasectomy. Future Oncol, 2020, 16(16s): 7-13.
57. Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol, 2011, 8(6): 378-382.
58. Samadzadeh Tabrizi N, Gallant B, Harris E, et al. Contemporary incidence of synchronous multiple primary lung cancers and survival in the era of lung cancer screening. Innovations (Phila), 2024, 19(1): 23-29.
59. Detterbeck FC, Nicholson AG, Franklin WA, et al. The IASLC Lung Cancer Staging Project: Summary of proposals for revisions of the classification of lung cancers with multiple pulmonary sites of involvement in the forthcoming eighth edition of the TNM classification. J Thorac Oncol, 2016, 11(5): 639-650.
60. Martini N, Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg, 1975, 70(4): 606-612.
61. Kozower BD, Larner JM, Detterbeck FC, et al. Special treatment issues in non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 2013, 143(5 Suppl): e369S-e399S.
62. Kang X, Zhang C, Zhou H, et al. Multiple pulmonary resections for synchronous and metachronous lung cancer at two Chinese centers. Ann Thorac Surg, 2020, 109(3): 856-863.
63. Nie Y, Wang X, Yang F, et al. Surgical prognosis of synchronous multiple primary lung cancer: Systematic review and meta-analysis. Clin Lung Cancer, 2021, 22(4): 341-350.
64. 姜格寧, 陳昶, 朱余明, 等. 上海市肺科醫院磨玻璃結節早期肺腺癌的診療共識(第一版). 中國肺癌雜志, 2018, 21(3): 147-159.Jiang G, Chen C, Zhu Y, et al. Shanghai pulmonary hospital experts consensus on the management of ground-glass nodules suspected as lung adenocarcinoma (version 1). Chin J Lung Cancer, 2018, 21(3): 147-159.
65. 韓丁培, 嚴越, 曹羽欽, 等. 加速康復外科理念在胸外科臨床實踐指導的瑞金醫院專家共識. 山東大學學報(醫學版), 2022, 60(11): 11-16.Han DP, Yan Y, Cao YQ, et al. Expert consensus of Ruijin Hospital on the concept of enhanced recoveryafter surgery in the clinical practice of thoracic surgery. J Shandong Univ (Health Sci), 2022, 60(11): 11-16.
66. 支修益, 劉倫旭, 中國胸外科圍手術期氣道管理指南(2020版)編寫委員會. 中國胸外科圍手術期氣道管理指南(2020版). 中國胸心血管外科臨床雜志, 2021, 28(3): 251-262.Zhi XY, Liu LX, Writing Committee of Chinese Guidelines for Perioperative Airway Management in Thoracic Surgery (2020 edition). Chinese guidelines for perioperative airway management in thoracic surgery (2020 edition). Chin J Clin Thorac Cardiovasc Surg, 2021, 28(3): 251-262.
67. 高樹庚. 加速康復外科在肺癌圍術期管理中的應用. 山東大學學報(醫學版), 2022, 60(11): 1-10.Gao SG. Application of enhanced recovery after surgeryin perioperative management of lung cancer. J Shandong Univ (Health Sci), 2022, 60(11): 1-10.
68. 郭儐, 劉志承, 羅鴻萍, 等. 智慧醫療時代ERAS發展的新機遇. 嶺南現代臨床外科, 2021, 21(3): 253-256.Guo J, Liu ZC, Luo HP, et al. New opportunities for ERAS in the era of intelligent medicine. Lingnan Mod Clin Surg, 2021, 21(3): 253-256.
69. 石文惠, 劉拓, 趙玉明. 數字療法應用與發展展望. 中國醫學前沿雜志(電子版), 2023, 15(12): 8-11.Shi WH, Liu T, Zhao YM. Application and development perspectives of digital therapeutics. Chin J Front Med Sci (Electronic Version), 2023, 15(12): 8-11.
70. 徐宜蕙, 張一帆, 李楊, 等. 美國FDA批準的數字療法產品臨床試驗設計研究. 中國醫學裝備, 2022, 19(11): 1-7.Xu YH, Zhang YF, Li Y, et al. Study on the design of clinical trial of approved DTx by FDA. Chin Med Equip, 2022, 19(11): 1-7.
71. Mogk JM, Matson TE, Caldeiro RM, et al. Implementation and workflow strategies for integrating digital therapeutics for alcohol use disorders into primary care: A qualitative study. Addict Sci Clin Pract, 2023, 18(1): 27.
72. Kumbara AB, Iyer AK, Green CR, et al. Impact of a combined continuous glucose monitoring-digital health solution on glucose metrics and self-management behavior for adults with type 2 diabetes: Real-world, observational study. JMIR Diabetes, 2023, 8: e47638.
73. 吳一龍, 陸舜, 程穎, 等. 非小細胞肺癌分子殘留病灶專家共識. 循證醫學, 2021, 21(3): 129-135.Wu YL, Lu S, Cheng Y, et al. Practice guideline and specialists, consensus expert consensus of molecular residual disease for non-small cell lung cancer. J Evid Based Med, 2021, 21(3): 129-135.
74. Gale D, Heider K, Ruiz-Valdepenas A, et al. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer. Ann Oncol, 2022, 33(5): 500-510.
75. Xia S, Ye J, Chen Y, et al. Parallel serial assessment of somatic mutation and methylation profile from circulating tumor DNA predicts treatment response and impending disease progression in osimertinib-treated lung adenocarcinoma patients. Transl Lung Cancer Res, 2019, 8(6): 1016-1028.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Chinese thoracic surgery expert consensus on rational diagnosis and treatment of pulmonary nodules with a diameter≤2 cm (2024)

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content